Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that data from the
University of Pennsylvania investigator sponsored Phase 1 safety study of Sangamo's zinc finger nuclease (ZFN) based product, SB-728-T, for HIV/AIDS were inadvertently and prematurely ...
[News-Medical.Net - 11/19/2009]